Lixte Biotechnology Holdings (FRA:8640) ROCE % : -108.52% (As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Lixte Biotechnology Holdings ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Lixte Biotechnology Holdings's annualized ROCE % for the quarter that ended in Mar. 2024 was -108.52%.

Lixte Biotechnology Holdings ROCE % Historical Data

The historical data trend for Lixte Biotechnology Holdings's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lixte Biotechnology Holdings ROCE % Chart

Lixte Biotechnology Holdings Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

-75.49

-84.98

-142.33

-130.58

-108.91

Lixte Biotechnology Holdings Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
ROCE %	Get a 7-Day Free Trial															-117.31	-195.39	-107.52	-90.58	-108.52

Lixte Biotechnology Holdings ROCE % Calculation

Lixte Biotechnology Holdings's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-4.65	/	( ( (5.25 - 0.374)	+	(3.951 - 0.288) )	/ 2 )
	=	-4.65	/	( (4.876	+	3.663)	/ 2 )
	=	-4.65	/	4.2695
	=	-108.91 %

Lixte Biotechnology Holdings's ROCE % of for the quarter that ended in Mar. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	-3.548	/	( ( (3.951 - 0.288)	+	(3.302 - 0.426) )	/ 2 )
	=	-3.548	/	( ( 3.663	+	2.876 )	/ 2 )
	=	-3.548	/	3.2695
	=	-108.52 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

Lixte Biotechnology Holdings (FRA:8640) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Lixte Biotechnology Holdings ROCE % Related Terms

Thank you for viewing the detailed overview of Lixte Biotechnology Holdings's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Lixte Biotechnology Holdings (FRA:8640) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lixte Biotechnology Holdings Inc (FRA:8640) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

LIXT:USA

Address

680 East Colorado Boulevard, Suite 180, Pasadena, CA, USA, 91101

Website

https://www.lixte.com

Lixte Biotechnology Holdings Inc is a drug discovery company that has a developed unique, proprietary, first-in-class protein phosphatase inhibitor, LB-100, as its lead clinical compound. LB-100 has potential widespread use as an anti-cancer agent when used alone and in combination with standard anti-cancer therapies, including cytotoxic drugs, radiation, and immune checkpoint blockers. The Company's product pipeline is primarily focused on inhibitors of protein phosphatases, used alone and in combination with cytotoxic agents and x-ray and immune checkpoint blockers.

Lixte Biotechnology Holdings (FRA:8640) Headlines

No Headlines